Velocity Stocks: Arotech Corporation (NASDAQ:ARTX), Shake Shack Inc. (NYSE:SHAK), Lam Research Corporation (NASDAQ:LRCX), Esperion Therapeutics (NASDAQ:ESPR), Halozyme Therapeutics (NASDAQ:HALO)


Arotech Corp. (NASDAQ: ARTX) reported Q2 EPS of ($0.04), $0.08 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $21.6 million versus the consensus estimate of $26.7 million. Arotech Corporation (NASDAQ:ARTX) shares moved up 1.85% in last trading session and ended the day at $2.20. ARTX Gross Margin is 30.60% and its has a return on assets of 1.60%. Arotech Corporation (NASDAQ:ARTX) quarterly performance is -21.15%.

Shake Shack Inc. (NYSE:SHAK) posted quarterly net income of $1.1 million, or $0.08 per share, versus $1.9 million, or $0.06 per share, in the year-ago period. Excluding non-recurring items, the company’s adjusted earnings came in at $0.09 per share. Shake Shack Inc. (NYSE:SHAK) ended the last trading day at $70.64. Company weekly volatility is calculated as 9.16% and price to cash ratio as 42.12. Shake Shack Inc. (NYSE:SHAK) showed a weekly performance of 0.96%.

RBC Capital reaffirmed their outperform rating on shares of Lam Research (NASDAQ:LRCX) in a research note issued to investors on Friday, MarketBeat.Com reports. They currently have a $76.00 price target on the stock. On 10 August, Lam Research Corporation (NASDAQ:LRCX) shares advanced 3.38% and was closed at $74.87. LRCX EPS growth in last 5 year was 6.40%. Lam Research Corporation (NASDAQ:LRCX) year to date (YTD) performance is -5.08%.

On 6 August, Esperion Therapeutics, Inc. (NASDAQ:ESPR), provided ETC-1002 (bempedoic acid) development program updates and financial results for the second quarter ended June 30, 2015.Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares advanced 16.31% in last trading session and ended the day at $68.32. ESPR has a return on assets of -26.70%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) quarterly performance is -34.50%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO), reported financial results for the second quarter ended June 30, 2015. Financial highlights include revenues of $43.4 million and net income of $3.0 million, or $0.02 per share, compared to revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share, for the second quarter of 2014. Halozyme Therapeutics, Inc. (NASDAQ:HALO) caters to the Healthcare space. It has a net profit margin of -69.50% and weekly performance is -8.34%. On the last day of trading company shares ended up $21.11. Halozyme Therapeutics, Inc. (NASDAQ:HALO) distance from 50-day simple moving average (SMA50) is -3.67%.


Leave a Reply

Your email address will not be published. Required fields are marked *